Metrics other than potency reveal systematic variation in responses to cancer drugs - Dataset (ID:20120)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Cell Line | log10[max. dose (M)] | R^2 (goodness of fit) | log10[EC50 (M)] | log10[IC50 (M)] | log10[GI50 (M)] | HillSlope | E_inf | E_max | AUC |
|---|---|---|---|---|---|---|---|---|---|---|
| Fascaplysin | MB 157 | -4.4776 | 0.9257 | -6.8596 | -6.8594 | -6.9090 | 2.5960 | 0.0000 | 0.0000 | 5.4423 |
| IKK16 | HCC38 | -4.1759 | 0.9833 | -5.4059 | -5.4061 | -5.5002 | 3.9990 | 0.0000 | 0.0000 | 6.7114 |
| Fascaplysin | HCC1143 | -4.4776 | 0.9804 | -6.4486 | -6.4482 | -6.5516 | 2.2170 | 0.0000 | 0.0000 | 5.7131 |
| Bortezomib | HCC1187 | -3.7773 | 0.9896 | -7.6223 | -7.6220 | -7.8008 | 3.0070 | 0.0000 | 0.0000 | 3.0973 |
| CGC-11144 | T47D | -3.1500 | 0.9900 | -6.8050 | -6.8048 | -6.9870 | 2.1540 | 0.0000 | 0.0000 | 3.3268 |
| Bortezomib | SUM159PT | -3.7773 | 0.9754 | -7.3913 | -7.3915 | -7.4495 | 1.5190 | 0.0000 | 0.0000 | 3.3800 |
| Imatinib | SUM159PT | -3.2480 | 0.9729 | -4.9070 | -4.9068 | -4.9231 | 3.9930 | 0.0000 | 0.0000 | 6.3954 |
| MG-132 | HCC1187 | -4.1759 | 0.9800 | -6.9169 | -6.9165 | -7.1022 | 1.7230 | 0.0000 | 0.0000 | 4.3524 |
| Sunitinib | SUM1315MO2 | -3.7773 | 0.9914 | -5.0033 | -5.0029 | -5.1409 | 3.6140 | 0.0000 | 0.0000 | 6.7848 |
| Fascaplysin | MDA-MB-175-VII | -4.4776 | 0.9647 | -6.4386 | -6.4390 | -6.6543 | 2.7690 | 0.0000 | 0.0000 | 5.4065 |
| IKK16 | SUM159PT | -4.1759 | 0.9378 | -5.8909 | -5.8905 | -5.9012 | 3.6300 | 0.0000 | 0.0000 | 5.8036 |
| Bortezomib | T47D | -3.7773 | 0.9910 | -7.3053 | -7.3057 | -7.4319 | 3.2440 | 0.0000 | 0.0000 | 3.3783 |
| Olomoucine II | LY2 | -3.8761 | 0.9242 | -5.1391 | -5.1392 | -5.2909 | 4.0000 | 0.0000 | 0.0000 | 7.0997 |
| Imatinib | BT-549 | -3.2480 | 0.9758 | -4.5030 | -4.5034 | -4.5287 | 3.7630 | 0.0000 | 0.0000 | 6.9489 |